1 |
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640.
|
2 |
吴国明,钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
3 |
Simeone JC, Nordstrom BL, Patel K, et al. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting[J]. Future Oncol, 2019, 15(30): 3491-3502.
|
4 |
孙泽辉,孙泽林,张 彦,等. 不同治疗方式的非小细胞肺癌患者一年存活率及生活质量调查分析[J]. 中国综合临床,2017, 33(2): 145-149.
|
5 |
De Ruysscher D, Faivre-Finn C, Nackaerts K, et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer[J]. Ann Oncol, 2020, 31(1): 41-49.
|
6 |
王 锐,周宏杨,武慧杰,等. 放化疗不同联合模式治疗非小细胞肺癌患者的疗效毒性反应及其预后因素分析[J]. 河北医学,2022, 28(7): 1118-1123.
|
7 |
石文波,曹 华,冉瑞智,等. 生物免疫疗法联合放化疗应用于局限期非小细胞肺癌治疗效果及对免疫功能的影响[J]. 临床肺科杂志,2017, 22(1): 18-21.
|
8 |
Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(23): 5792-5806.
|
9 |
中国抗癌协会肺癌专业委员会,中华医学会肿瘤学分会肺癌学组. Ⅲ期非小细胞肺癌多学科诊疗专家共识( 2019版)[J]. 中华肿瘤杂志,2019, 41(12): 881-890.
|
10 |
放射肿瘤学免疫联合治疗专家讨论小组,艾星浩,蔡 勇,等. 放疗联合免疫治疗非小细胞肺癌:前沿学术问题专家交流共识[J]. 中国肺癌杂志,2020, 23(6): 532-540.
|
11 |
Singh S, Gupta R, Singh TP, et al. A comparative study of concurrent chemo-radiotherapy with or without neoadjuvant chemotherapy in treatment of locally advanced non small cell lung cancer[J]. Gulf J Oncolog, 2021, 37(1): 62-69.
|
12 |
Cortiula F, Reymen B, Peters S, et al. Immunotherapy in unresectable stage Ⅲ non-small-cell lung cancer: state of the art and novel therapeutic approaches[J]. Ann Oncol, 2022, 33(9): 893-908.
|
13 |
Steuer CE, Ramalingam SS. Advances in immunotherapy and implications for current practice in non-small-cell lung cancer[J]. JCO Oncol Pract, 2021, 17(11): 662-668.
|
14 |
郭燕蓉. 放化疗联合生物免疫疗法对非小细胞肺癌患者血管内皮抑素及免疫功能的影响[J]. 中国药物与临床,2019, 19(7): 1115-1117.
|
15 |
靳明伟,徐在革. DC-CIK生物免疫疗法用于甲状腺癌术后的疗效及对患者IL-16、TNF水平的影响[J]. 实用癌症杂志,2020, 35(3): 490-493.
|
16 |
张华安,周晓芳,蒋易君,等. DC-CIK生物免疫疗法对甲状腺癌术后免疫调节的作用[J]. 中国现代普通外科进展,2020, 23(11): 898-901.
|
17 |
陈 静. DC-CIK细胞免疫疗法联合NP化疗对晚期非小细胞肺癌患者疾病控制率及KPS评分的影响[J]. 医药论坛杂志,2019, 40(2): 85-87.
|
18 |
艾月琴,江龙委,赵 华,等. 术后序贯DC-CIK细胞治疗对局部晚期非小细胞肺癌术后生存率及免疫功能的影响[J]. 中国医药导报,2018, 15(29): 100-103; 100-103, 107.
|
19 |
张伟萍,应海峰,贺茹依,等. 细胞生物免疫治疗联合化疗对非小细胞肺癌患者凋亡相关基因和免疫功能的影响[J]. 中国基层医药,2021, 28(6): 806-810.
|
20 |
蒋玉欢,何本超,郑志刚,等. 改良Miccoli微创术联合术后DC-CIK治疗甲状腺癌疗效及对患者血清Gal-3、sIL-2R水平的影响[J]. 陕西医学杂志,2020, 49(11): 1417-1421.
|
21 |
Azghadi S, Daly ME. Radiation and immunotherapy combinations in non-small cell lung cancer[J]. Cancer Treat Res Commun, 2021, 26: 100298.
|
22 |
Tian L, Wang W, Yu B, et al. Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer[J]. BUON, 2020, 25(5): 2364-2370.
|
23 |
陆婉玲,李小龙,党亚正,等. DC-CIK免疫疗法联合放化疗治疗中晚期非小细胞肺癌疗效观察[J]. 疑难病杂志,2020, 19(8): 804-807; 804-807, 827.
|
24 |
高会霞. 同步放化疗联合DC-CIK治疗局部晚期非小细胞肺癌的临床疗效分析[J]. 临床肺科杂志,2018, 23(9): 1596-1600.
|
25 |
周 宾,丛云燕. 生物免疫疗法联合放化疗治疗局限性非小细胞肺癌的疗效及对生活质量的影响[J]. 癌症进展,2021, 19(18): 1900-1902.
|
26 |
张伟萍,应海峰,贺茹依,等. 细胞生物免疫治疗联合化疗对非小细胞肺癌患者凋亡相关基因和免疫功能的影响[J]. 中国基层医药,2021, 28(6): 806-810.
|